Clinical Double-Blind Randomized Controlled Trial of Quji Tongluo Decoction in Intervention of Branch Retinal Vein Occlusion Secondary Macular Edema
- Conditions
- Retinal vein occlusion
- Registration Number
- ITMCTR2000003673
- Lead Sponsor
- Eye Hospital, China Academy of Chinese Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Between 40 and 70 years old;
2. It conforms to the Western medicine diagnostic criteria of non-ischemic branch retinal vein occlusion and conforms to the TCM syndrome differentiation criteria of phlegm and blood stasis. The course of the disease is more than 2 weeks;
3. OCT examination showed macular edema, and the thickness of the central retina was more than 250µm;
4. Agree to participate in this clinical trial and sign an informed consent form.
1. There is severe turbidity of the refractive medium;
2. Those with loss of central vision in the late course of the disease;
3. Combined with other macular diseases of the retina;
4. Persons who are allergic or possibly allergic to drugs;
5. Patients suffering from severe cardiovascular and cerebrovascular diseases or severely impaired liver and kidney function and systemic failure, or combined with severe global diseases, cannot tolerate relevant eye examinations and surgical treatment;
6. Women during pregnancy and lactation;
7. Patients who are participating in clinical trials of other drugs or who have used similar Chinese medicines and other treatments.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method visual function;
- Secondary Outcome Measures
Name Time Method TCM syndrome score;Recurrence time of macular edem;OCT measures macular edema;Vision-related quality of life in patients with macular edema secondary to branch retinal vein occlusion Questionnaire (The BRVO ME on Quality of Life (BMIQ) Questionnaire);The number of anti-VEGF drugs injected by the patient;FA detection of blood vessels in fundus;Patient's blood lipids (total cholesterol, triglycerides, high-density lipoprotein, low-density fat);